In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae

Treatment of infections caused by multi-drug resistant (MDR) enterobacteria remains challenging due to the limited therapeutic options available. Drug repurposing could accelerate the development of new urgently needed successful interventions. This work aimed to identify and characterise novel drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómara-Lomero, Marta, López-Calleja, Ana Isabel, Rezusta, Antonio, Aínsa, José Antonio, Ramón-García, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475115/
https://www.ncbi.nlm.nih.gov/pubmed/37660210
http://dx.doi.org/10.1038/s41598-023-39647-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475115/
https://www.ncbi.nlm.nih.gov/pubmed/37660210
http://dx.doi.org/10.1038/s41598-023-39647-9

Ejemplares similares